Cambridge Healthtech Institute’s 2nd Annual

Early Cancer Surveillance

Broad Cancer Screening of Undiagnosed Populations

August 22-23, 2023

 

Current guidelines call for screening for only five types of cancer, and in each case for one type of cancer per screen. This means that the majority of cancers have no screening and far too often when cancer is detected it is later-stage with much lower prognosis compared to patients when cancer is detected much earlier. Identification of tumors early, prior to metastasis and increased mutational burden, translates to significantly improved chances of successful treatment. Very good progress is being made with screenings based on liquid biopsies, with a wide range of different biomarkers being investigated. The most common approach involves sequencing of circulating DNA -- or, methylated DNA -- but other classes of biomarkers, including mRNA, proteins, metabolites, and others, as well as combinations of these classes, are also being developed. Considerable challenges remain, including questions related to validation, health economics, access, and widespread implications for what could be an extremely disruptive impact on cancer care.

 

Coverage will include, but is not limited to:

 

  • The potential for Multi-Cancer Early Detection
  • Platforms based on sequencing of DNA and methylated DNA
  • Platforms based on RNA, metabolites, proteins, and combination biomarkers
  • Validation of screening technologies and biomarker selection
  • Issues related to false negatives and false positive results
  • Questions related to health economics, cost, and cost effectiveness
  • Effectiveness of different biomarker categories and combinations
  • Roadmaps for commercial introduction and competitiveness

 

The deadline for priority consideration is January 30, 2023.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

Opportunities for Participation:

 

 

For more details on the conference, please contact:

Phillips Kuhl

Chief Executive Officer

Cambridge Healthtech Institute

Phone: 781-972-5410

Email: pkuhl@cambridgeinnovationinstitute.com

 

For sponsorship information, please contact:

Companies A-M

Phillip Zakim-Yacouby

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: 781-247-1815

Email: philzy@cambridgeinnovationinstitute.com

 

Companies N-Z

Jon Stroup

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: 781-972-5483

Email: jstroup@healthtech.com